Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 165

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 165
---
 may not be able to raise additional funds or enter into such other arrangements when needed or on favorable terms, or at all. If we are unable to raise additional capital or enter into such arrangements when needed, we could be forced to delay, limit, reduce or terminate our research and development programs or future commercialization efforts, or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. 

Components of Results of Operations

Operating Expenses 

Research and Development Expenses 

To date, our research and development expenses consist primarily of external and internal costs related to the development of our SNÅP platform and our product candidates and development programs. Our research and development expenses primarily include: 

•external costs, including:

oexpenses incurred in connection with conducting clinical trials, including investigator grants and site payments for time and pass-through expenses and expenses incurred under agreements with contract research organizations (CROs), central laboratories and other vendors and service providers engaged to conduct our trials;

oexpenses incurred in connection with the discovery and preclinical development of our product candidates, including under agreements with third parties, such as consultants and CROs; 

ocosts associated with consultants for chemistry, manufacturing and controls (CMC) development, and other services;

othe cost of manufacturing compounds for use in our preclinical studies, including under agreements with third parties, such as consultants and third-party manufacturers; and

ocosts related to compliance with drug development regulatory requirements; and

•internal costs, including: 

oemployee-related expenses, including salaries, related benefits, travel and share-based compensation expenses for employees engaged in research and development functions; 

othe costs of laboratory supplies and acquiring, developing and manufacturing preclinical study materials; and 

ofacilities, depreciation and other indirect expenses, which include allocated expenses for rent and maintenance of facilities and supplies. 

We expense research and development expenses in the periods in which they are incurred. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external expenses on a development program and other program-specific basis. However, we do not track internal costs on a program-specific basis because these costs primarily relate to compensation, early research and consumable costs, which are deployed across multiple programs under development. 

105

Research and development activities are central to our business model. There are numerous factors associated with the successful development of